Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5706460 | 0.89 | PTPN1 (0.48) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29401221 | 0.89 | PTPN1 (0.48) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29400612 | 0.89 | PTPN1 (0.48) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL5494326 | 0.88 | MDM4 (0.47) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29401878 | 0.88 | CASP3 (0.47) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL1738291 | 0.88 | MDM4 (0.47) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL8078352 | 0.87 | TLR2 (0.50) | MDM4TP53MDM2 | |
| SCHEMBL29398837 | 0.87 | MDM4 (0.46) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29083320 | 0.87 | CASP3 (0.48) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29996002 | 0.87 | TLR2 (0.50) | MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148505-B2 | Method of α-selective glycosylation | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-04-03 | — | — | US | disclosed |
| EP-1626053-B1 | METHOD OF ALPHA-SELECTIVE GLYCOSYLATION | JAPAN SCIENCE & TECH AGENCY (JP) | 2011-07-06 | — | — | EP | disclosed |
| US-20060122379-A1 | Method of alpha-selective glycosylation | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1626053-A2 | METHOD OF ALPHA-SELECTIVE GLYCOSYLATION | Japan Science and Technology Agency (JP) | 2006-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122379-A1 | Method of alpha-selective glycosylation | FUT6, ST6GAL1, FUT5 | MDM4 3479/4885TP53 2933/4885CASP3 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.